HUTCHMED (China) Limited (AIM:HCM)
239.11
+5.61 (2.40%)
Sep 8, 2025, 3:02 PM GMT+1
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $277.68M USD in the half year ending June 30, 2025, a decrease of -47.89%. This brings the company's revenue in the last twelve months to $602.20M, down -1.41% year-over-year. In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%.
Revenue (ttm)
$602.20M
Revenue Growth
-1.41%
P/S Ratio
4.56
Revenue / Employee
$332.52K
Employees
1,811
Market Cap
2.01B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
Genus | 672.80M |
Oxford Nanopore Technologies | 204.69M |
HUTCHMED (China) News
- 3 days ago - HUTCHMED (China) Ltd (HCM) to Present New Data at Major Oncology Conferences | HCM stock news - GuruFocus
- 3 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer ... - GuruFocus
- 3 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 - GlobeNewsWire
- 14 days ago - HUTCHMED CEO takes leave of absence; CFO Johnny Cheng appointed acting CEO - Seeking Alpha
- 14 days ago - HUTCHMED Announces CEO Leave of Absence and Interim Leadership Change | HCM stock news - GuruFocus
- 14 days ago - HUTCHMED Announces Appointment of Acting Chief Executive Officer - GlobeNewsWire
- 19 days ago - HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ... - GuruFocus
- 19 days ago - HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - GlobeNewsWire